What's included in the Shed Membership
in the next five or so years, or if insurance coverage improves, we could see a noticeable jump in adoption. Also noting the cost barrier, Keychains Madoff explains that payment options and other platforms are easing that burden for some consumers
Where Injected GLP-1 Therapies Still Lead Weekly injections such as Wegovy and Mounjaro remain ahead in: Higher average long-term weight-loss percentages More established long-term safety data Real-world evidence across large patient populations Because injections have been studied for over a decade, they currently hold the strongest clinical outcomes in obesity care
Retatrutide adds glucagon receptor activation to the GIP and GLP-1 effects seen with tirzepatide
Mounjaro (tirzepatide) GLP-1 + GIP In SURMOUNT-1 (72 weeks), average weight loss at the highest dose was often quoted around: ~22.5% (highest dose) What that looks like: If you start at 100 kg , ~22.5% is about 2223 kg lost on average
This makes it a promising option for those seeking significant and sustained weight loss
.png)
